Impact of age and comorbidities on the efficacy of FC and FCR regimens in chronic lymphocytic leukemia

被引:9
作者
Strugov, Vladimir [1 ]
Stadnik, Elena [1 ,2 ]
Virts, Yulia [1 ]
Andreeva, Tatyana [1 ]
Zaritskey, Andrey [1 ,2 ]
机构
[1] Almazov Natl Med Res Ctr, Inst Hematol, Akkuratova St 2, St Petersburg 197341, Russia
[2] Pavlov First St Petersburg State Med Univ, Div Hematol, St Petersburg 197022, Russia
关键词
CLL; Chronic lymphocytic leukemia; CIRS-G; Comorbidities; FCR; MYELOID-LEUKEMIA; SURVIVAL; TRIAL; CELL; FLUDARABINE; CHEMOIMMUNOTHERAPY; CYCLOPHOSPHAMIDE; PROGRESSION; EXPRESSION; GUIDELINES;
D O I
10.1007/s00277-018-3409-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
CLL is an aging-associated neoplasm with median age at diagnosis >65years. Little is known about safety and efficacy of FC/FCR regimens in elderly CLL patients with multiple comorbidities. We retrospectively revised medical records of 90 patients treated with FC/FCR regimens in our clinic. Data on demographic and biological characteristics, comorbidities, response to therapy, and treatment-associated adverse events were analyzed. Compared to FC, FCR yielded higher rates of OR (93.6 vs. 81.4%, p=.109) and CR (72.3 vs. 46.5%, p=.018). This translated in longer EFS (median 52 vs. 19months, p=<.001) and OS (median 89 vs. 45months, p=.001). Elderly patients (65 years) had more comorbidities and higher median CIRS-G score (7 vs. 4, p<.001). However, no association was found between CIRS-G score and survival. Decreased renal function was associated with dismal prognosis in patients treated with FCR.
引用
收藏
页码:2153 / 2161
页数:9
相关论文
共 35 条
[31]   Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia [J].
Thurmes, Paul ;
Call, Timothy ;
Slager, Susan ;
Zent, Clive ;
Jenkins, Gregory ;
Schwager, Susan ;
Bowen, Deborah ;
Kay, Neil ;
Shanafelt, Tait .
LEUKEMIA & LYMPHOMA, 2008, 49 (01) :49-56
[32]   Chemoimmunotherapy May Overcome the Adverse Prognostic Significance of 11q Deletion in Previously Untreated Patients With Chronic Lymphocytic Leukemia [J].
Tsimberidou, Apostolia-Maria ;
Tam, Constantine ;
Abruzzo, Lynne V. ;
O'Brien, Susan ;
Wierda, William G. ;
Lerner, Susan ;
Kantarjian, Hagop M. ;
Keating, Michael J. .
CANCER, 2009, 115 (02) :373-380
[33]   Aging of the Microenvironment Influences Clonality in Hematopoiesis [J].
Vas, Virag ;
Senger, Katharina ;
Doerr, Karin ;
Niebel, Anja ;
Geiger, Hartmut .
PLOS ONE, 2012, 7 (08)
[34]   The Origin and Evolution of Mutations in Acute Myeloid Leukemia [J].
Welch, John S. ;
Ley, Timothy J. ;
Link, Daniel C. ;
Miller, Christopher A. ;
Larson, David E. ;
Koboldt, Daniel C. ;
Wartman, Lukas D. ;
Lamprecht, Tamara L. ;
Liu, Fulu ;
Xia, Jun ;
Kandoth, Cyriac ;
Fulton, Robert S. ;
McLellan, Michael D. ;
Dooling, David J. ;
Wallis, John W. ;
Chen, Ken ;
Harris, Christopher C. ;
Schmidt, Heather K. ;
Kalicki-Veizer, Joelle M. ;
Lu, Charles ;
Zhang, Qunyuan ;
Lin, Ling ;
O'Laughlin, Michelle D. ;
McMichael, Joshua F. ;
Delehaunty, Kim D. ;
Fulton, Lucinda A. ;
Magrini, Vincent J. ;
McGrath, Sean D. ;
Demeter, Ryan T. ;
Vickery, Tammi L. ;
Hundal, Jasreet ;
Cook, Lisa L. ;
Swift, Gary W. ;
Reed, Jerry P. ;
Alldredge, Patricia A. ;
Wylie, Todd N. ;
Walker, Jason R. ;
Watson, Mark A. ;
Heath, Sharon E. ;
Shannon, William D. ;
Varghese, Nobish ;
Nagarajan, Rakesh ;
Payton, Jacqueline E. ;
Baty, Jack D. ;
Kulkarni, Shashikant ;
Klco, Jeffery M. ;
Tomasson, Michael H. ;
Westervelt, Peter ;
Walter, Matthew J. ;
Graubert, Timothy A. .
CELL, 2012, 150 (02) :264-278
[35]   Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial [J].
Zenz, Thorsten ;
Haebe, Sonja ;
Denzel, Tina ;
Mohr, Julia ;
Winkler, Dirk ;
Buehler, Andreas ;
Sarno, Antonio ;
Groner, Silja ;
Mertens, Daniel ;
Busch, Raymonde ;
Hallek, Michael ;
Doehner, Hartmut ;
Stilgenbauer, Stephan .
BLOOD, 2009, 114 (13) :2589-2597